Regeneron to Buy 23andMe After Bankruptcy, Data Breach

Regeneron Pharmaceuticals has agreed to acquire nearly all assets of 23andMe, including its biobank with genetic data from over 15 million customers, for $256 million in a bankruptcy auction. The acquisition, excluding 23andMe's Lemonaid Health telehealth subsidiary, is expected to close in the third quarter of 2025 pending court and regulatory approvals. Regeneron will maintain 23andMe’s consumer DNA testing services and uphold its privacy policies, overseen by a court-appointed privacy ombudsman. The deal follows a significant 2023 data breach at 23andMe and heightened concerns from government officials and privacy advocates about customer data security. Once valued at over $6 billion, 23andMe filed for Chapter 11 bankruptcy in March 2025 after financial losses and business challenges. Regeneron intends to use the acquired genetic data to enhance its drug development research while emphasizing privacy and ethics.